Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    12697856 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
Condition: Neoplasms
Interventions: Drug: Bevacizumab;   Drug: BAY 43-9006
2 Completed Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Conditions: Ovarian Neoplasm;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: Bevacizumab;   Drug: BAY 43-9006

Indicates status has not been verified in more than two years